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CPC— ELBOW PAIN AND SICKLE-CELL ANEMIA
Figure 3. Bone scan showing increased uptake superior 
to the kidney.
sclerosis associated with infarction in sickle-cell dis­
ease. Infection is a more likely possibility, and because 
of the clinical context, Salmonella might be seriously 
considered. Salmonella infections are usually more 
aggressive than this, but the possibility of a chronic 
infection or a partially treated acute infection should 
certainly be included in the differential diagnosis.
Neoplastic disease is also a consideration. It is un­
likely that the patient had a primary tumor of bone, but 
a primary neoplastic process of the joint capsule, such 
as a synovial sarcoma, cannot be excluded. Metastatic 
tumor is also a possibility. However, metastases to the 
limbs are uncommon, and in this young patient, a me­
tastasis to the elbow seems statistically unlikely. In this 
age group, it is also important to mention the possibility 
of leukemia or lymphoma, for these processes can in­
volve the joint space, producing radiographic findings 
similar to those found in today's patient.
The gallium scan and the radionuclide bone scan 
added some important additional information. I will ask 
Dr. Kumar to give you these results.
Dr. Bharath Kumar: A bone scan was performed with 
technetium-99m methylene diphosphonate. There was 
a focus of increased activity superior to the left kidney
(Figure 3), which most probably represents accumu­
lation of the tracer in an infarcted, atrophic spleen. This 
is a well-recognized entity in patients with sickle-cell 
disease and should not be confused with a lesion in the 
rib. There was uniform distribution of activity in the 
lumbar spine and in both sacroiliac joints. There was 
increased activity in the left elbow compared with the 
right. This corresponds to the destructive process with 
some periosteal elevation and mottled lucencies in the 
bony cortex of the distal left humerus that Dr. Jost de­
scribed. Dr. Jost excluded bony infarction on the basis 
of the radiographic findings and commented that the 
primary differential possibilities included infection, 
metastatic disease, and leukemia or lymphoma that 
involves bone. The scintigraphic findings in the left 
elbow were nonspecific in that they were compatible 
with all three of these possibilities. The pathophysio­
logic basis for an abnormal bone scan includes in­
creased bone blood flow, increased bone turnover, or 
both. Therefore, any process that results in either or 
both of the aforementioned will result in a focus of in­
creased activity in a bone scan. The scan also showed 
a focus of increased activity in the distal right femur and 
another in the mid-shaft of the right tibia. In this patient, 
these foci of increased activity could be secondary ei­
ther to bone infarction in the reparative phase or to 
osteomyelitis. It is not possible on a bone scan to dif­
ferentiate these two entities.
To aid in this distinction, a gallium scan was per­
formed. The anterior image of both tibiae made 48 hours 
after administration of gallium-67 citrate showed no 
evidence of increased activity in the mid-shaft of the 
right tibia, where the focus of increased activity was 
noted on the bone scan. Similarly, there was no evi­
dence of increased activity in the distal right femur. 
Increased activity of an intensity greater than that seen 
on the bone scan would have favored a diagnosis of 
osteomyelitis. In this patient, the absence of dispro­
portionately increased activity suggests that the bone 
scan abnormalities were secondary to healing bone 
infarcts.
The gallium image of the left anterior chest and arm 
(Figure 4) demonstrated increased activity in the left 
elbow corresponding to the bone scan abnormality in 
this region. This patient, however, had undergone biopsy 
of the lateral epicondyle of the left humerus during the 
four-day interval between the two scans. This compli­
cates the differential diagnosis, since the focus of in­
creased activity could be secondary to a hyperemic 
response to the biopsy itself rather than to accumulation 
of gallium at a site of either skeletal infection or neo­
plastic infiltration of bone. Additional scintigraphic 
findings in this patient included increased activity in the 
soft tissues around the proximal humerus. This was also 
seen in the soft tissues surrounding both proximal
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femora. A history of intramuscular injections in these 
regions was elicited, and the soft tissue foci of in­
creased activity were believed to represent the injection 
sites with or without associated soft tissue infection. 
There was a focus of increased activity in the left breast 
with additional foci of increased activity in the region 
of the left axilla. Potential explanations of these findings 
include either an infectious process in the breast with 
reactive inflammatory changes in the axillary nodes or 
a malignant process with metastatic disease in the 
axillary nodes. The malignant process could well be 
leukemic or lymphomatous infiltration. Another finding, 
which may be of some importance in regard to this 
patient, was the symmetrically increased activity seen 
in the long bones and joints of both legs. This finding has 
been reported in patients with leukemia and reflects 
gallium-67 accumulation in infiltrated bone marrow.
Dr. Deuel asked me to review briefly the mechanism 
of gallium localization in inflammatory lesions and to 
comment on its usefulness in the evaluation of patients 
with either inflammatory or malignant disease. Gal­
lium-67 originally was investigated as a tumor-scanning 
agent [7,8] and has been widely used for this purpose. 
Early reports [8,9] were enthusiastic about its potential 
as a tumor-seeker, even though they also mentioned 
the problem of nonspecificity, since gallium localizes 
in many types of inflammatory processes. To give a few 
examples, gallium-67 studies yield positive results in 
80 to 90 percent of primary lesions of bronchogenic 
carcinoma, irrespective of the cell type of the tumor. 
Abnormal uptake in one or more lesions was demon­
strated in 88 percent of untreated patients with Hodg­
kin’s disease [10]. A sensitivity of 87 percent has been 
reported for the detection of metastatic sites in patients 
with seminoma [11]. Although the pattern of diffusely 
increased bony uptake is not specific for leukemia, 76 
percent of patients with more than 75 percent blasts in 
the marrow demonstrated this pattern in one study [12]. 
Other tumors in which gallium imaging has been found 
to be useful include histiocytic and lymphocytic lym­
phomas, Burkitt’s lymphoma, and melanomas. The 
sensitivity of gallium imaging for detecting hepatomas 
exceeds 90 percent. A major problem with gallium 
imaging is that a large fraction of the administered tracer 
is excreted into the gastrointestinal tract. Residual 
gallium-67 in the colon may lead to false-positive in­
terpretations or may obscure activity in abdominal tumor 
foci. This problem has particularly limited the value of 
gallium-67 imaging for the staging of lymphomas.
Although enthusiasm for gallium-67 as a tumor- 
seeker has somewhat diminished, enthusiasm for its 
use in localizing inflammatory disease has increased. 
Numerous published reports [13 -19 ], including a few 
from this institution, have attested to the low frequency 
of false-positive and false-negative diagnoses with this
Figure 4. Gallium scan. Left anterior view of chest and 
arm .
technique. The sensitivity exceeds 90 percent but the 
false-positive rate tends to increase when gallium 
imaging is used for routine screening of febrile pa­
tients.
In the evaluation of patients with suspected ab­
scesses, gallium-67 citrate is administered intrave­
nously, usually in a dose of 3 to 5 mCi, and imaging is 
performed 24 and 48 hours later. Images can be made 
as soon as four to six hours after injection in emergency 
situations. However, early images are not ordinarily 
obtained because the body background at this time is 
rather high. Since the tracer is normally excreted into 
the intestine, we advocate a bowel preparation similar 
to that used before barium enema examinations to 
permit better evaluation of the abdomen and pelvis. 
Adequate bowel preparation, combined with serial 
examinations at 24, 48, and sometimes 72 hours, de­
creases the frequency of false-positive results, since 
intracolonic activity frequently changes location on 
serial images.
How does gallium-67 localize in inflammatory le­
sions? The mechanisms have not been fully elucidated, 
but the following observations suggest a useful hy­
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pothesis. When gallium-67 citrate is injected intrave­
nously, it is bound almost immediately to plasma pro­
teins, especially transferrin [20,21]. Hotter et al. [22] 
have shown that there is an exchange of transferrin- 
bound gallium-67 with lactoferrin. It has also been 
shown that gallium-67 localization in experimental 
abscesses is either absent or delayed in leukopenic 
animals [20).Tsan etal. [23] have demonstrated that 
gallium-67 binds to the plasma membrane of neutro­
philic leukocytes that migrate to the site of inflamma­
tion. Some microorganisms, in particular Staphylo­
coccus aureus, have been shown to accumulate gal­
lium-67 directly [24]. Therefore, increased protein 
turnover, leukocyte accumulation, and bacterial uptake 
appear to play important roles in the localization of 
gallium in abscesses and other infectious processes.
What did the bone and gallium scans contribute to the 
management of this patient? First, they helped exclude 
osteomyelitis in the right proximal tibia and distal femur. 
The scans suggested the presence of an infarcted 
spleen. Additional sites of increased activity were 
identified in the breast and in the ipsilateral axilla, 
thereby raising the possibility of a coexisting infectious 
or malignant process. Neoplastic and inflammatory 
lesions cannot be differentiated solely on the basis of 
gallium-67 uptake. Finally, the possibility of a leukemic 
process with marrow infiltration was raised by the 
finding of increased activity in the long bones of both 
legs.
Dr. Deuel: Infection was considered throughout the 
hospital course to be a strong possibility as the under­
lying illness complicating this patient’s sickle-cell 
anemia. Dr. Richard Markham will discuss why patients 
with sickle-cell anemia have an increased propensity 
to infection, what infections are likely to occur in these 
patients, and the diagnostic procedures used in the 
clinical management of this patient.
Dr. Richard Markham: Before discussing this partic­
ular patient, I would like to review briefly the infectious 
disease problems that are peculiar to patients with 
sickle-cell disease. The propensity for infections with 
encapsulated organisms, particularly with pneumo­
cocci, to develop in these patients is well established 
[25]. To understand why patients with sickle-cell dis­
ease have this increased risk, it is first necessary to be 
aware of the basis for natural immunity to these or­
ganisms. In the pre-antibiotic era it was determined that 
protection against pneumococcal infection best cor­
related with high levels of antibody directed at the 
polysaccharide capsules of the organisms [26]. At that 
time, therapeutic trials with pneumococcal capsular- 
specific antibody were undertaken. It was not until much 
later that it was discovered that pneumococci pos­
sessed the ability to activate the alternative complement 
pathway, even in the absence of specific antibodies
[27]. It was then postulated that opsonization via the 
alternative complement pathway, by promoting more 
efficient phagocytosis, could in fact be protective 
against low-level exposure to these organisms.
In the late 1960s, Winklestein and Drachman [28] 
showed that serum from patients with sickle-cell dis­
ease lacked the ability to promote phagocytosis of 
pneumococci via the alternative pathway. In these 
studies, the investigators mixed granulocytes from a 
normal patient with pneumococci and antibody-free 
serum from either a patient with sickle-cell disease or 
a normal patient. It is apparent that in the presence of 
normal serum, phagocytosis of pneumococci pro­
ceeded (Figure 5, left), whereas there is very little ev­
idence of phagocytosis when the organisms were in­
cubated in serum from patients with sickle-cell disease 
(Figure 5, right). The investigators put these observa­
tions in more quantitative terms by looking at the per­
centage of granulocytes that in fact contained phago- 
cytized pneumococci. In the presence of normal serum, 
35 percent of granulocytes contained pneumococci; 
in the presence of serum from patients with sickle-cell 
disease, only 10 percent of phagocytes contained 
bacteria. This defect in the activation of the alternative 
complement pathway is not specific for pneumococci, 
and more traditional activators of the alternative com­
plement pathway, such as zymosan, have also been 
shown to be ineffective in the serum of patients with 
sickle-cell disease [29].
The component of the alternative complement 
pathway that is deficient in patients with sickle-cell 
disease has not been clarified at this time. It is known 
that when serum from patients with sickle-cell disease 
is used, normal activation of the classic complement 
pathway occurs in the presence of specific antibody. 
The deficiency therefore must involve those comple­
ment components that are not shared by the alternative 
and classic complement pathways. There is some ev­
idence for factor B deficiency in these patients, although 
there are conflicting results on that observation [30,31]. 
Because the classic complement pathway is intact, and 
since this pathway is activated by antibody, it is easy 
to understand the rationale for giving pneumococcal 
vaccine to patients with sickle-cell disease to com­
pensate for the defect in alternative complement 
pathway activation.
Since patients with sickle-cell anemia are function­
ally asplenic, they would be subject to the same risk of 
pneumococcal sepsis seen in other asplenic patients 
[32]. However, the risk of pneumococcal infection 
appears to be greater in patients with sickle-cell dis­
ease, and it is this additional risk that is best explained 
by the defect in alternative complement pathway acti­
vation.
The other infectious disease commonly encountered
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